RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.
about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapyTargeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cellsValidation of TPX2 as a potential therapeutic target in pancreatic cancer cells.Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerPhenotypic Screening Approaches to Develop Aurora Kinase Inhibitors: Drug Discovery PerspectivesCross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle AssemblyScientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerImpacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancerAurora kinase A in gastrointestinal cancers: time to targetTherapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancerSmall molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathwaysAurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.Evaluation of the medicinal herb Graptopetalum paraguayense as a treatment for liver cancerStudy of RNA interference inhibiting rat ovarian androgen biosynthesis by depressing 17alpha-hydroxylase/17, 20-lyase activity in vivoConditional Aurora A deficiency differentially affects early mouse embryo patterningMitotic catastrophe and cell death induced by depletion of centrosomal proteins.Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.Dysregulating IRES-dependent translation contributes to overexpression of oncogenic Aurora A Kinase.A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in miceDriver mutations: a roadmap for getting close and personal in pancreatic cancerAurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumorsAurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway.Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells.Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseThe long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration.Neuroprotective effects of 17β-estradiol rely on estrogen receptor membrane initiated signals.Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosisPhosphorylation-dependent regulation of ALDH1A1 by Aurora kinase A: insights on their synergistic relationship in pancreatic cancerAurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3Molecular mechanisms of pancreatic carcinogenesis.Aurora A and B kinases as targets for cancer: will they be selective for tumors?Targeting Aurora kinases in ovarian cancer.Predictive factors for response to docetaxel in human breast cancers.Differential proteomic alterations between localised and metastatic prostate cancer.Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells.A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
P2860
Q21245716-A86DDA79-1867-4CCC-89F5-ACF27C85F333Q21245757-9E65E722-D665-477D-B26B-824EB31464CDQ24650802-21E5018E-B68F-4EA5-8752-8C9BB475F1ADQ24657439-C7AB44EE-A2AB-4DEF-B88C-FD5987B36AEBQ26771369-59A02BCB-6C16-4034-A3BC-CFBDF5F42E2EQ26771374-0EE6994C-FA4A-4C3B-AF6D-DD54CC36A108Q26784060-E7A20CDA-B6B6-430B-B9DF-B728191C6290Q26830681-D743F389-3AED-4250-8F7F-04CAEBC58514Q26864277-3DFAB34D-3707-4EFE-A1FA-8088C7577932Q27004357-55640358-0BFF-4B55-84A9-6D261D3C7E08Q27317155-DD14D486-C708-499E-AF24-7CC285DA6CA1Q27853386-9FBAFD04-2D38-4C60-87B1-55337F387C1FQ28545854-DF2384A9-E144-4AE4-BD80-E734FCC5BC39Q28582335-CBD39FBF-B8D7-42DE-BF17-75649931F8AAQ28584840-5DA065A8-BC62-473A-8F81-5DDB29DB8CA8Q30539373-8C996077-3CEF-47E3-B9C2-E59ADE87E994Q33258367-C0CF754C-53EB-4922-9AA8-605EFE25C8BDQ33412196-16CDCC62-D321-4D3E-9886-352B832AC0D8Q33944846-647F9B84-7A92-4364-966F-D62C9F73A18FQ34448958-2767D616-BFBB-4BFE-9270-19BFC455553EQ34544275-4239E6C4-BD73-4F06-84EB-CA5E7F86F2FBQ34582122-48EAE9DE-D040-448C-BCE4-71C367620EF2Q34621867-96FB537A-FE06-40D8-AB54-D81D6E7F7999Q35070067-1093946D-053A-456C-9EB0-7EACB8C7D2D3Q35149675-91025574-9147-4816-92FF-92A462EFC14FQ35168142-1B605DE6-6237-4539-898B-37AE82DA99CFQ35666453-86E95F99-48C2-483E-922E-7828F328C33CQ35676802-E4FEF5E4-C197-4E6A-80C9-60642EA1972DQ35793635-0CBE9EE7-08FF-459E-B0D9-971917D23670Q35871967-F0244505-C522-434C-A6B3-F18A4F670262Q36179938-390B09A3-0B9A-46F0-9E9D-C079FF4288D9Q36279199-38431049-FCF6-45ED-8F4B-E8A338F769C0Q36289893-CD27A313-0081-499D-9F47-29FAB0DB524EQ36347882-663A1D83-03EC-4386-803F-D1D319448AC9Q36352091-FD0B5239-198F-4FA6-B59D-A49AD1DC1544Q36379376-55DF70D7-2040-4852-B78B-59A94DE7C6B6Q36521963-0414E3B7-F569-43E7-89BE-68ACCBCD5261Q36553042-EA91C5C5-6798-488C-8DD3-77396541A360Q36604655-D60FFE67-B4B8-4A77-BFB1-D6C94F6B20A9Q36726212-6C4FD77F-B9A3-4C16-AC68-E287E249993A
P2860
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
RNA interference targeting aur ...... human pancreatic cancer cells.
@en
type
label
RNA interference targeting aur ...... human pancreatic cancer cells.
@en
prefLabel
RNA interference targeting aur ...... human pancreatic cancer cells.
@en
P2093
P50
P1433
P1476
RNA interference targeting aur ...... human pancreatic cancer cells
@en
P2093
Fuyuhiko Motoi
Hideyuki Saya
Makoto Sunamura
Noriyuki Ohmura
Tatsuo Hata
Tomotoshi Marumoto
P304
P356
10.1158/0008-5472.CAN-04-3981
P407
P577
2005-04-01T00:00:00Z